Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic Kidney Disease-Associated Anemia Condition: Chronic kidney disease not on dialysis |
Dose: Intravenous or Subcutaneous – 0.45 mcg/kg Frequency: every 4 weeks Note: Recommended starting dose. Consider initiating Erythropoiesis-Stimulating Agent treatment only when the hemoglobin level is less than 10 g/dL. If the hemoglobin level exceeds 10 g/dL, reduce or interrupt Erythropoiesis-Stimulating Agent dose and use the lowest dose sufficient to reduce the need for red blood cell transfusions. |
|
Indication: Chronic Kidney Disease-Associated Anemia Condition: Chronic kidney disease on dialysis |
Dose: Intravenous or Subcutaneous – 0.45 mcg/kg Frequency: once weekly Note: Recommended starting dose. Initiate Erythropoiesis-Stimulating Agent treatment when the hemoglobin level is less than 10 g/dL. If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of Erythropoiesis-Stimulating Agent. The intravenous route is recommended for patients on hemodialysis. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic Kidney Disease-Associated Anemia Age: pediatric (less than 18 years) |
Dose: Subcutaneous or Intravenous Injection – 0.45 mcg/kg Frequency: once weekly Note: Initiate treatment when the hemoglobin level is less than 10 g/dL. If the hemoglobin level approaches or exceeds 12 g/dL, reduce or interrupt the dose. |
|
Indication: Chronic Kidney Disease-Associated Anemia Age: pediatric (less than 18 years) Condition: Patients not receiving dialysis |
Dose: Subcutaneous or Intravenous Injection – 0.75 mcg/kg Frequency: every 2 weeks Note: Initiate treatment when the hemoglobin level is less than 10 g/dL. If the hemoglobin level approaches or exceeds 12 g/dL, reduce or interrupt the dose. |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic Kidney Disease-Associated Anemia Condition: Chronic Kidney Disease not on dialysis |
Dose: Intravenous or Subcutaneous – 0.45 mcg/kg Frequency: every 4 weeks Note: Consider initiating Erythropoiesis-Stimulating Agent treatment only when the hemoglobin level is less than 10 g/dL; If the hemoglobin level exceeds 10 g/dL, reduce or interrupt Erythropoiesis-Stimulating Agent dose and use the lowest dose sufficient to reduce the need for red blood cell transfusions |
|
Indication: Chronic Kidney Disease-Associated Anemia Condition: Chronic Kidney Disease on dialysis |
Dose: Intravenous or Subcutaneous – 0.45 mcg/kg Frequency: once weekly Note: Initiate Erythropoiesis-Stimulating Agent treatment when the hemoglobin level is less than 10 g/dL; If the hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt the dose of Erythropoiesis-Stimulating Agent; Intravenous route recommended for patients on hemodialysis |
Administration
- Given as injection
- Must be administered by healthcare professionals
Side Effect
- Fatigue (33%)
- Diarrhea (22%)
- Edema (21%)
- Fever (19%)
- Dizziness (14%)
- Arthralgia (13%)
- Headache (12%)
- Death (10%)
- Infectious disease (24%)
- Hyper/Hypotension (20%)
- Spasm (17%)
- Upper respiratory infection
- Headache (15%)
- Diarrhea
- Vomiting (14%)
- Nausea (11%)
- Peripheral edema
- Dyspnea (10%)
- Abdominal pain (10%)
- Myalgia (8%)
- Hypertension (3.7%)
- Pneumonia (3%)
- Dyspnea (2%)
- Vomiting (2%)
- Pulmonary embolism (1.3%)
- Arthralgia
- Cough
- Fatigue (9%)
- Limb pain (8%)
- Dizziness
- Fever (7%)
- Death (6%)
- Edema (6%)
- Anemia
- DVT
- red cell aplasia (5.6%)
- Cardiac arrest
- Cardiac dysrhythmia
- Congestive heart failure (5%)
- Myocardial infarction
- CVA(2%)
- Hypertensive encephalopathy (0.6%)
- Seizure (0.6%)
- Chronic renal failure patients
- Hypertensive encephalopathy (Less than 1%)
- Seizure (Less than 1%)
- Tumor progression
- Venous thromboembolism
- Immune hypersensitivity reaction (rare )
- Injection site thrombosis
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
ACE Inhibitors (Captopril, Enalapril, Lisinopril, Ramipril, Benazepril, Fosinopril, Quinapril, Perindopril), angiotensin II receptor antagonists
|
Antagonism of hypotensive effect and increased risk of hyperkalemia
|
|
Ethanol
|
Interaction mentioned but specific effect not detailed
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Uncontrolled Hypertension
|
Risk of cardiovascular events
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store at 2°C to 8°C. Do not freeze. Do not shake. Protect from light; store Darbepoetin Alfa in the carton until use. Do not use Darbepoetin Alfa that has been shaken or frozen.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.